What Ipca Laboratories Limited does

Ipca Laboratories Limited is an Indian vertically-integrated pharmaceutical company, founded in 1949 and headquartered in Mumbai, that manufactures and exports over 80 Active Pharmaceutical Ingredients (APIs) and more than 350 finished formulations across therapeutic areas including pain management, rheumatology, antimalarials, haircare, and — most recently — diabetic wound care via the Diulcus (Esmolol Hydrochloride) product licensed from NovaLead. The company operates 15-16 manufacturing facilities in India approved by UK-MHRA, EDQM-Europe, WHO-Geneva, Health Canada, TGA-Australia, SAHPRA-South Africa, and other stringent regulators, supported by wholly-owned subsidiaries in the United States (Bayshore Pharmaceuticals, Pisgah Labs) and the United Kingdom, and an in-house clinical research function established in 2007 with Novel Drug Delivery System R&D capabilities.

The company monetizes through three core streams: API exports to global pharmaceutical majors (including AstraZeneca, GlaxoSmithKline, Merck, Roche, and Sanofi Aventis), branded formulations in India where it holds leading positions in Pain, Rheumatology, Antimalarials, and Haircare (with five brands in IQVIA's top 300 Indian pharma brands as of October 2023), and generic formulations distributed internationally through subsidiaries and channel partners across 120+ countries. Go-to-market combines B2B enterprise field sales for API and institutional generic buyers with direct-to-consumer branded formulation marketing in India, supplemented by a 2024 IP licensing partnership with NovaLead to commercialize Diulcus domestically. The publicly listed entity (BSE: IPCALAB) is led by Executive Chairman Premchand Godha, has approximately 12,654 employees, and has progressively expanded ESG commitments including UN Global Compact participation in 2026 and an EcoVadis Committed rating.

Name

Ipca Laboratories Limited

Legal name

Ipca Laboratories Limited

Website

https://ipca.com

Company type

Public

Founded year

1949

Operating status

Operating

Headcount range

10,001+ employees

Short description

Ipca Laboratories Limited is a publicly listed Indian pharmaceutical manufacturer founded in 1949, producing 80+ APIs and 350+ formulations across pain, rheumatology, antimalarial, haircare, and diabetic wound care therapies for global pharma majors and Indian patients across 120+ countries.

Ownership category

akta.pro rank

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices10 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Active Pharmaceutical Ingredients (APIs): Manufactures and exports over 80 APIs to global pharmaceutical companies for use in their formulations. APIs are produced at fully-automated facilities approved by major regulatory authorities.
2. Branded Formulations - India: Markets over 350 formulations through leading brands in Pain, Rheumatology, Antimalarials and Haircare therapy segments in India. 5 formulations rank amongst top 300 brands of Indian Pharmaceutical Market per IQVIA.
3. Branded Formulations - International: Markets formulations internationally through subsidiaries and partnerships in regulated and emerging markets.
4. Generic Formulations: Manufactures and supplies generic drugs globally, expanding the generic space to offer competitive pricing in various markets.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Ipca Laboratories manufactures and supplies over 80 Active Pharmaceutical Ingredients (APIs) and 350+ finished dosage formulations covering cardiovascular, antimalarial, diuretic, pain management, rheumatology, and haircare therapeutic segments. The company operates 15 manufacturing facilities in India approved by major regulatory authorities (UK-MHRA, EDQM, WHO, US-FDA) and exports APIs to global pharmaceutical companies while marketing branded formulations in India and generic formulations internationally. In-house clinical research services and recently launched specialty products such as Diulcus for Diabetic Foot Ulcer treatment complement the core pharmaceutical manufacturing offering.

Product overview

Ipca Laboratories is a fully-integrated pharmaceutical company manufacturing over 350 formulations and 80 APIs for various therapeutic segments. The product portfolio is organized into two core divisions: Active Pharmaceutical Ingredients (APIs) including cardiovascular, antimalarial, and antihypertensive drugs; and Formulations encompassing Branded Formulations (India and International), and Generics. The company has leading positions in Pain, Rheumatology, Antimalarials, and Hair care therapy in India. Additional services include Clinical Research and the recently launched Diulcus® drug product for diabetic foot ulcer treatment.

Differentiator

Problem solved

Functional benefit

Products and services

• Active Pharmaceutical Ingredients (APIs) Manufacture and supply of over 80 APIs covering cardiovascular, antimalarial, diuretic, and antihypertensive therapeutic areas; one of the world's largest manufacturers of over a dozen APIs including Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine Sulphate, Losartan, Metoprolol Succinate and Tartrate, Pyrantel Salts, and Propranolol, exported to global pharmaceutical companies from fully-automated, regulatory-approved manufacturing facilities.
• Pharmaceutical Formulations Manufacture of over 350 formulations across various dosage forms including oral solids, powder for suspension, and small volume injections (dry and liquid); supplied through branded (India and International) and generic channels.
• Branded Formulations - India Leading branded formulations in the Indian pharmaceutical market targeting Pain, Rheumatology, Antimalarials, and Hair care therapy segments; 5 formulations rank amongst top 300 brands of Indian Pharmaceutical Market per IQVIA October 2023.
• Branded Formulations - International Formulations marketed internationally across regulated territories through subsidiaries and partnerships in regulated and emerging markets.
• Generic Formulations Generic pharmaceutical products manufactured for global markets with cost competitiveness across multiple therapeutic segments.
• Clinical Research Services Full-fledged in-house clinical research function established since 2007, undertaking all clinical trial activities from concept to publication. Focus areas include Cardiovascular, Pain Management, Malaria, Infections, Endocrinology, Gynecology, Psychiatry, Dyslipidemia, and Dermatology; specializes in exploring hidden potential of existing, non-patented products.
• Diulcus® (Esmolol Hydrochloride) Patented, repurposed topical formulation of Esmolol Hydrochloride (originally approved for Tachycardia) for the treatment of Diabetic Foot Ulcer (DFU); Phase III trial demonstrated 20% higher incidence of complete wound closure versus Standard of Care. Launched in India in August 2024 through an exclusive IP licensing arrangement with NovaLead Pharma.

Quantifiable outcome

• 5 formulations rank amongst top 300 brands of Indian Pharmaceutical Market per IQVIA October 2023
• +2 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• NovaLead PharmacoreOEM/ Whitelabel/ Licensing Partner · 1 August 2024Exclusive IP licensing arrangement for Indian market where Ipca markets NovaLead's patented repurposed drug Diulcus (Esmolol Hydrochloride) for Diabetic Foot Ulcer treatment. The drug was developed through Phase III trials and approved for its superior wound closure efficacy. Ipca committed to making Diulcus available in India from August 2024.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Lupin: India-headquartered pharma company with a leading API business (cardiovascular, diuretics, anti-TB) and a global finished formulation franchise, with US and Emerging Markets as core growth geographies.
• Aurobindo Pharma: India-based vertically integrated pharmaceutical company with a comparable mix of API manufacturing (one of the world's largest) and finished formulation sales across regulated and emerging markets, supplying many of the same global generics customers.
• Dr. Reddy's Laboratories: Indian pharma major with strong API manufacturing capabilities (including in cardiovascular and antimalarial therapies) and a global generics business; a closely comparable vertically integrated competitor with deep US, EU and Emerging Markets presence.
• Cadila Healthcare (Zydus Lifesciences): Vertically integrated Indian pharmaceutical group with APIs, complex generics and biosimilars, serving similar therapeutic areas (cardiovascular, anti-infectives) across the same regulated and emerging markets as Ipca.
• Glenmark Pharmaceuticals: India-based pharma company with an API/generic formulation model, presence in the US, EU, India and Emerging Markets, and a comparable focus on cardiovascular, dermatology and respiratory therapy segments.
• Sun Pharmaceutical Industries: India's largest pharmaceutical company by revenue, operating a similarly integrated API + formulation model with leading US generics presence (Taro) and a global manufacturing footprint spanning regulated and emerging markets.
• Cipla: Major Indian pharmaceutical manufacturer with significant API production and a broad branded and generic formulation portfolio, including antimalarials and respiratory drugs, serving over 80 countries with strong US/UK regulated-market exposure.

Broad incumbents

• Apotex: Canadian generic pharmaceutical manufacturer with vertically integrated API and formulation operations serving the US, Canada and Emerging Markets — a comparable mid-to-large scale North-America-anchored generic+API player.
• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with significant internal API production across small molecules, operating at a much larger scale than Ipca in the same US, EU and Emerging Markets generic channels.
• Sandoz (Novartis division): Global generics and biosimilars powerhouse with broad API manufacturing capabilities, competing with Ipca in the same off-patent small-molecule and biosimilar markets but at substantially greater scale and geographic reach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ipca

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ipca Laboratories Limited